ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dolutegravir

Also written as “GSK1349572”, “DTG” and “Dolutegravir 50 mg”.

Its studies are mostly in Infections · HIV Infections · Malaria · Acquired Immunodeficiency Syndrome · Tuberculosis, led by 3 companies.

Drug pageDolutegravir: every studyAll 170 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 13, 201766 company-led studies, 3 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline643 open or runningphase 4since Oct 13, 2017Nov 5, 2007Sep 14, 2032phase 3 · NCT07393659
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jun 4, 2024Jun 4, 2024none ahead
Viatrisits history only10 open or runningearly phase 1since Jul 28, 2021Jul 28, 2021none ahead

Also a collaborator on its studies: PPD Development, LP, Johnson & Johnson and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Oct 16, 2008.

  1. Jan 6, 2017Phase 3 study in HIV InfectionsNCT03016533 · 100 enrolled · United States, Botswana, Brazil and more
  2. Mar 8, 2017Phase 1 study in InfectionsNCT03078556 · 154 enrolled · United States
  3. Oct 13, 2017Phase 4 study in InfectionsNCT03314064 · 43 enrolled · Russian Federation
  4. Jan 5, 2018Phase 3 study in HIV InfectionsNCT03446573 · 743 enrolled · United States, Australia, Belgium and more
  5. Sep 21, 2018Phase 3 study in HIV InfectionsNCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
  6. Jan 22, 2019Phase 1 study in HIV InfectionsNCT03816696 · 16 enrolled · United States
  7. Apr 17, 2019Phase 1 study in HIV InfectionsNCT03921723 · 22 enrolled · United Kingdom
  8. May 8, 2019Phase 3 study in HIV InfectionsNCT03945981 · 131 enrolled · United States
  9. Jul 11, 2019Phase 3 study in HIV InfectionsNCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
  10. Apr 28, 2021Phase 2 study in HIV InfectionsNCT04871113 · 62 enrolled · United States, Argentina, Brazil and more
  11. Dec 7, 2022Phase 2 study in HIV InfectionsNCT05674656 · 20 planned · United States
  12. Jun 9, 20232 phase 3 studies in HIV InfectionsNCT05911360, NCT05917509
  13. Jul 19, 2023Phase 3 study in HIV InfectionsNCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
  14. Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda

Ahead

  1. Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 64 GlaxoSmithKline leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07393659HIV Infections · Romania, South Africa, Uganda3RecruitingSep 14, 2032197
NCT05979311HIV Infections · Argentina, Belgium, Denmark and more3Active, not recruitingApr 15, 2026463
NCT05917509HIV Infections · United States, Argentina, Canada and more3CompletedSep 16, 2025171
NCT05911360HIV Infections · United States, Austria, Belgium and more3CompletedJan 23, 2026205
NCT05674656HIV Infections · United States2RecruitingJun 1, 202620
NCT04871113HIV Infections · United States, Argentina, Brazil and more2CompletedOct 27, 202262
NCT04021290HIV Infections · United States, Argentina, Belgium and more3CompletedApr 23, 2021493
NCT03945981HIV Infections · United States3CompletedApr 29, 2020131
NCT03921723HIV Infections · United Kingdom1CompletedJul 25, 201922
NCT03816696HIV Infections · United States1CompletedMar 30, 201916
NCT03682848HIV Infections · Kenya, South Africa, Thailand3CompletedDec 1, 202132
NCT03446573HIV Infections · United States, Australia, Belgium and more3CompletedMay 20, 2019743
NCT03314064Infections · Russian Federation4CompletedOct 1, 201843
NCT03078556Infections · United States1CompletedAug 18, 2017154
NCT03016533HIV Infections · United States, Botswana, Brazil and more3CompletedDec 24, 2024100
NCT02893488Infections · United States1CompletedNov 1, 201620
NCT02741557Infections · United States1CompletedOct 24, 2016118
NCT02738931Infections · United States1CompletedJun 201630
NCT02715479Infections · United States1CompletedMay 201614
NCT02227238HIV Infections · Argentina, Brazil, Chile and more3CompletedAug 2, 2017627
NCT02185300Infections · United States1CompletedSep 201415
NCT02178592Infections · Argentina, Brazil, Mexico and more3CompletedNov 2, 2017113
NCT02105987Infections · United States, Canada, Puerto Rico3CompletedApr 2015555
NCT02082808Infections · United States1CompletedMay 201412
NCT02075593Infections · Russian Federation, Spain3CompletedOct 22, 20184
NCT02064374Infections · United States1CompletedMay 201430
NCT01967771Infections · United States1CompletedJan 201416
NCT01910402Infections · United States, Argentina, Canada and more3CompletedSep 22, 2015499
NCT01622790Infections · United States1CompletedAug 201266
NCT01568892HIV Infections · United States3CompletedOct 31, 201230
NCT01536873Infections · United States, Austria, Belgium and more–CompletedSep 23, 2016200
NCT01498861Infections · United States1CompletedMar 201216
NCT01499199Infections · United States3CompletedOct 201213
NCT01467531Infections · United States1CompletedFeb 201228
NCT01467518Infections · Canada1CompletedFeb 201211
NCT01449929Infections · United States, France, Germany and more3CompletedApr 22, 2013488
NCT01425099Infections · United States1CompletedOct 201112
NCT01382238Infections · United States1CompletedAug 201120
NCT01366547Infections · United States1CompletedJul 201118
NCT01353716Infections · United States1CompletedApr 201216
NCT01332565Infections · United States1CompletedJun 201110
NCT01328041Infections · United States, Belgium, Canada and more3CompletedMay 2012183
NCT01283100Infections · United States1WithdrawnMar 20110
NCT01231516Infections · United States, Argentina, Australia and more3CompletedFeb 4, 2013724
NCT01231529Infections · United States1CompletedJun 4, 201116
NCT01227824Infections · United States, Australia, Canada and more3CompletedFeb 6, 2012828
NCT01214993Infections · United States1CompletedNov 201038
NCT01209065Infections · United States1CompletedNov 201027
NCT01098513Infections · United States1CompletedJun 201024
NCT01098526Infections · United States1CompletedMay 26, 201012
NCT01068925Infections · United States1CompletedApr 5, 201018
NCT00996021Healthy Subjects · United States1CompletedNov 200942
NCT00951015Infections · United States, France, Germany and more2CompletedFeb 26, 2010208
NCT00950859Infections · United States, Canada, France and more2CompletedNov 201051
NCT00942136HIV Infections · United States1CompletedSep 200924
NCT00883935Healthy Volunteer · United States1CompletedJun 200924
NCT00867152Healthy Volunteer · United States1CompletedMay 200917
NCT00858455Healthy Volunteer · United States1CompletedMar 200916
NCT00774735Infections · United States1CompletedDec 200830
NCT00774111Healthy Subjects · United States1CompletedDec 200816

How it is read

Names in the registry

  • “GSK1349572”, 20 entries
  • “Dolutegravir”, 12 entries
  • “DTG”, 6 entries
  • “Dolutegravir 50 mg”, 4 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.